
Fredrik Hellem Schjesvold
- Head of Oslo Myeloma Center; PhD, MD
- +47 996 97 796, 221 19680
Fredrik Schjesvold, MD, PhD, is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. He earned his medical degree from the University of Oslo in 2001 and did his hematological training at the Department of Hematology at Oslo University Hospital. He has previously headed the units of hematology at Diakonhjemmet hospital and Bærum hospital in Norway.
Dr. Schjesvold is an international expert on Multiple Myeloma, with one of Europe’s largest centers for clinical research in this disease. This includes being the national coordinator of 30 clinical myeloma trials, and in addition being the principal investigator of 3 large myeloma studies. He is also an expert on light chain amyloidosis.
Dr. Schjesvold is on the steering committee of the Nordic Myeloma Study Group, where he leads the clinical trial task force. He leads the Norwegian Myeloma Group and is the main author of the Norwegian Myeloma Guidelines. He is also a member of the International Myeloma Working Group, the International Myeloma Society, the European Hematology Association, and the American Society of Hematology.
Publications 2021
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 100 (1), 297-302
DOI 10.1007/s00277-020-04302-0, PubMed 33106909
Publications 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 99 (8), 1793-1804
DOI 10.1007/s00277-020-04149-5, PubMed 32613281
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Am J Hematol (in press)
DOI 10.1002/ajh.26083, PubMed 33368455
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Lancet Oncol, 22 (1), 142-154
DOI 10.1016/S1470-2045(20)30680-X, PubMed 33301738
Melflufen for relapsed and refractory multiple myeloma
Expert Opin Investig Drugs, 29 (10), 1069-1078
DOI 10.1080/13543784.2020.1808884, PubMed 32924646
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019
Eur J Haematol, 105 (4), 434-448
DOI 10.1111/ejh.13464, PubMed 32557833
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
Eur J Haematol, 104 (5), 443-458
DOI 10.1111/ejh.13379, PubMed 31880006
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma
Future Oncol, 16 (11), 631-641
DOI 10.2217/fon-2020-0024, PubMed 32141766
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Haematologica (in press)
DOI 10.3324/haematol.2020.253450, PubMed 32586908
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Haematologica, 105 (12), 2879-2882
DOI 10.3324/haematol.2019.240374, PubMed 33256392
Publications 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Lancet, 394 (10214), 2096-2107
DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Lancet Oncol, 20 (6), e302-e312
DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e459-e469
DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol, 20 (6), 781-794
DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e448-e458
DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689
Publications 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Lancet, 393 (10168), 253-264
DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303
Publications 2017
Immunologiske mekanismer for drap av kreftceller
Tidsskr Nor Laegeforen, 137 (1), 58
DOI 10.4045/tidsskr.16.0963, PubMed 28073239
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
Leukemia, 31 (10), 2114-2121
DOI 10.1038/leu.2017.69, PubMed 28232741
Publications 2016
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737
Publications 2015
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
Cancer Res, 75 (16), 3268-78
DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231
Publications 2014
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
Eur J Immunol, 44 (9), 2625-37
DOI 10.1002/eji.201444659, PubMed 24846412
Publications 2013
[Investigation of anemia]
Tidsskr Nor Laegeforen, 133 (6), 610
DOI 10.4045/tidsskr.13.0256, PubMed 23552139
[Investigation of amyloidosis]
Tidsskr Nor Laegeforen, 133 (3), 266
DOI 10.4045/tidsskr.13.0044, PubMed 23381155
Publications 2012
A woman in her seventies with reduced general condition, dyspnoea and generalised pain
Tidsskr Nor Laegeforen, 132 (17), 1969-72
DOI 10.4045/tidsskr.11.0608, PubMed 23007363
Publications 2009
[Erythrocytosis as a problem]
Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
DOI 10.4045/tidsskr.09.1196, PubMed 19935946
Publications 2008
[High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
Tidsskr Nor Laegeforen, 128 (12), 1392-6
PubMed 18552900